Santin Alessandro D, Bellone Stefania, Siegel Eric R, McKenney Jesse K, Thomas Maria, Roman Juan J, Burnett Alexander, Tognon Germana, Bandiera Elisabetta, Pecorelli Sergio
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205-7199, USA.
Clin Cancer Res. 2007 Jun 1;13(11):3339-46. doi: 10.1158/1078-0432.CCR-06-3037.
To evaluate the expression levels of claudin-3 and claudin-4, the low- and high-affinity receptors, respectively, for the cytotoxic Clostridium perfringens enterotoxin (CPE) in uterine carcinosarcomas and explore the potential for targeting these receptors in the treatment of this aggressive uterine tumor.
We analyzed claudin-3 and claudin-4 receptor expression at mRNA and protein levels in flash frozen and formalin-fixed, paraffin-embedded carcinosarcoma specimens. Recombinant CPE was used as a novel therapy against chemotherapy-resistant carcinosarcoma cell lines in vitro. The therapeutic effect of sublethal doses of CPE was studied in severe combined immunodeficient mouse xenografts harboring large s.c. carcinosarcomas.
All flash-frozen carcinosarcoma biopsies (12 of 12) and short-term carcinosarcoma cell lines evaluated overexpressed claudin-3 and claudin-4 by quantitative reverse transcription-PCR. Membranous immunoreactivity for claudin-4 protein expression was documented in 80% (20 of 25) of primary tumors and 100% (6 of 6) of the metastatic carcinosarcomas, whereas negligible staining was found in normal endometrial cells. Regardless of their resistance to chemotherapeutic agents, all short-term carcinosarcoma cell lines tested died within 1 h of exposure to 3.3 microg/mL of CPE in vitro. Intratumoral injections of well-tolerated doses of CPE in large s.c. carcinosarcoma xenografts led to large areas of tumor cell necrosis and tumor disappearance in all treated animals.
Claudin-3 and claudin-4 receptors are highly overexpressed in carcinosarcoma. These proteins may offer promising targets for the use of CPE as a novel type-specific therapy against this biologically aggressive variant of endometrial cancer.
评估子宫癌肉瘤中分别作为细胞毒性产气荚膜梭菌肠毒素(CPE)低亲和力和高亲和力受体的claudin-3和claudin-4的表达水平,并探索靶向这些受体在治疗这种侵袭性子宫肿瘤中的潜力。
我们分析了速冻及福尔马林固定、石蜡包埋的癌肉瘤标本中claudin-3和claudin-4受体在mRNA和蛋白水平的表达。重组CPE被用作针对体外化疗耐药癌肉瘤细胞系的新型疗法。在携带大型皮下癌肉瘤的严重联合免疫缺陷小鼠异种移植模型中研究了亚致死剂量CPE的治疗效果。
通过定量逆转录PCR评估,所有速冻癌肉瘤活检标本(12例中的12例)和短期癌肉瘤细胞系均过表达claudin-3和claudin-4。在80%(25例中的20例)的原发性肿瘤和100%(6例中的6例)的转移性癌肉瘤中记录到claudin-4蛋白表达的膜免疫反应性,而在正常子宫内膜细胞中发现染色可忽略不计。无论对化疗药物的耐药性如何,所有测试的短期癌肉瘤细胞系在体外暴露于3.3μg/mL的CPE后1小时内均死亡。在大型皮下癌肉瘤异种移植模型中瘤内注射耐受性良好剂量的CPE,导致所有治疗动物出现大面积肿瘤细胞坏死和肿瘤消失。
claudin-3和claudin-4受体在癌肉瘤中高度过表达。这些蛋白可能为将CPE用作针对这种生物学侵袭性子宫内膜癌变体的新型类型特异性疗法提供有前景的靶点。